Page 2 - Agenus News Today

Agenus Inc. (AGEN) said it has triggered the second development milestone payment under global licensing agreement with Bristol Myers Squibb for BMS-986442. Agenus will receive a $25 million cash payment from Bristol Myers Squibb with the dosing of the first patient in the phase 2 dose expansion portion of the CA115-001 trial.

BNP Paribas Arbitrage SNC lowered its position in Agenus Inc. (NASDAQ:AGEN – Free Report) by 61.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 360,232 shares of the biotechnology company’s stock after selling 582,214 shares during the period. BNP Paribas Arbitrage SNC owned 0.10% of […]

Agenus (NASDAQ:AGEN – Get Free Report) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation. Profitability This table compares Agenus and […]

Genus plc (OTCMKTS:GENSF – Get Free Report) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 400 shares, an increase of 33.3% from the October 31st total of 300 shares. Based on an average daily volume of 200 shares, the short-interest ratio is […]

Researchers have discovered a new plant species in the genus ‘Impatiens’ (Balsaminaceae) in Kalakkad Mundanthurai Tiger Reserve, Chennai. The plant is found only in the Agasthyamalai region in the southern Western Ghats. The species is named ‘Impatiens Karuppusamyi’ after S Karuppusamy for his contributions to the taxonomy of South Indian angiosperms.

Agenus Inc. ( NASDAQ:AGEN ) shareholders will have a reason to smile today, with the analysts making substantial...

Genus plc (LON:GNS – Get Free Report) declared a dividend on Thursday, September 7th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, November 9th will be given a dividend of GBX 21.70 ($0.27) per share on Friday, December 8th. This represents a yield of 0.97%. The ex-dividend date is Thursday, November 9th. This is a boost […]

Key Highlights Include Promising Clinical Data and Anticipated Regulatory Filings

Cognito Therapeutics, a neurotechnology company birthed out of MIT, is pioneering breakthrough technology that may be able to slow the progression of Alzheimer’s disease.

A combination immunotherapy developed by biotech company Agenus administered before surgery destroyed over 80% of a tumor before it was removed.